文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

酒精室间隔消融术后肥厚型梗阻性心肌病患者长期生存分析

Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

该单中心回顾性研究纳入2000年5月至2017年6月接受超声引导下酒精室间隔消融(PTSMA)的952例症状性肥厚型梗阻性心肌病(HOCM)患者,随访6.0±5.0年。结果显示估计5年、10年、15年生存率分别为95.8%、88.3%、79.7%,无心血管事件生存率分别为98.6%、96.5%、92.3%,无心脏事件生存率分别为98.9%、97.0%、96.5%。结论认为PTSMA安全且长期生存良好,可作为外科肌切除术的合理替代。

要点

  • PTSMA术后估计5年生存率95.8%,10年88.3%,15年79.7%。
  • 估计5年无心血管事件生存率98.6%,无心脏事件生存率98.9%。
  • 术后静息和Valsalva压差均急性显著下降(p<0.0001)。

核心结论

  • PTSMA被证实为安全手术,症状持续改善且长期生存极佳,可作为HOCM患者外科肌切除术的合理替代。

研究设计与样本

  • 单中心回顾性研究,2000年5月至2017年6月共952例症状性HOCM患者接受超声引导下PTSMA,年龄55.7±14.9岁,59.2%男性,73.3% NYHA III或IV级,50.3%有晕厥史,10.3%有心脏性猝死家族史,全部患者完成6.0±5.0年临床随访。

主要发现

  • 注入酒精2.1±0.4 cc,最大肌酸激酶升高872±489 U/l。
  • 2例(0.21%)在术后3天和33天死亡,100例(10.50%)植入永久起搏器。
  • 静息压差从63.9±38.2 mm Hg acutely降至33.6±29.8 mm Hg,Valsalva压差从104.6±44.0 mm Hg降至56.5±41.0 mm Hg(p<0.0001)。
  • 随访期间164例(17.2%)再次消融,18例(1.9%)外科肌切除术,49例(5.10%)植入ICD。

临床怎么用

  • 对于症状性HOCM患者,PTSMA可有效降低左室流出道压差并改善症状,长期生存良好,可作为外科肌切除术的合理替代选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alcohol-induced infarction for treatment of symptomatic hypertrophic obstructive cardiomyopathy (HOCM) was discussed as a risk factor for increased cardiac mortality during follow-up. OBJECTIVES: This study sought to report on long-term survival after echo-guided alcohol septal ablation (percutaneous transluminal septal myocardial ablation [PTSMA]) in symptomatic patients with HOCM. METHODS: Between May 2000 and June 2017, PTSMA with alcohol injection was performed in 952 patients (age 55.7 ± 14.9 years; 59.2% men; 73.3% New York Heart Association functional class III or IV; 50.3% syncope; 10.3% sudden cardiac death in family). Clinical follow-up after 6.0 ± 5.0 years was achieved in all patients. RESULTS: We injected 2.1 ± 0.4 cc of alcohol. Maximal creatine kinase rise was 872 ± 489 U/l. Two (0.21%) patients died 3 and 33 days after ablation. Permanent pacemaker was implanted in 100 (10.50%) patients. Echo gradients were acutely reduced from 63.9 ± 38.2 mm Hg to 33.6 ± 29.8 mm Hg at rest and from 104.6 ± 44.0 mm Hg to 56.5 ± 41.0 mm Hg at Valsalva (p < 0.0001, each). During follow-up, 164 (17.2%) patients underwent reablation due to the planned staged procedure, 18 (1.9%) patients underwent surgical myectomy, and 49 (5.10%) patients underwent cardioverter-defibrillator implantation. Seventy patients died: causes of death were identified as noncardiovascular in 50, stroke related in 6, and cardiac in 14 patients. Estimated 5-year survival was 95.8%, estimated 5-year survival free of cardiovascular events was 98.6%, and an estimated 5-year survival free of cardiac events was 98.9%. Corresponding values at 10 years were 88.3%, 96.5%, and 97.0%, and at 15 years were 79.7%, 92.3%, and 96.5%. CONCLUSIONS: In this study, PTSMA could be proofed as a safe procedure with ongoing symptomatic improvement and excellent long-term survival. Therefore, PTSMA is a reasonable alternative to surgical myectomy in HOCM.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Batzner A, Pfeiffer B, Neugebauer A, et al. Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. J Am Coll Cardiol. 2018. PMID: 30545446. doi:10.1016/j.jacc.2018.09.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。